Detalle Publicación

ART%EF%BF%BD%EF%BF%BDCULO

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

Autores: Cortes, J.; Calvo, V.; Ramirez-Merino, N.; O'Shaughnessy, J.; Brufsky, A.; Robert, N.; Vidal, M.; Munoz, E.; Perez, J.; Dawood, S.; Saura, C.; Di Cosimo, S.; González Martín, Antonio; Bellet, M.; Silva, O. E.; Miles, D.; Llombart, A.; Baselga, J.
Título de la revista: ANNALS OF ONCOLOGY
ISSN: 0923-7534
Volumen: 23
Número: 5
Páginas: 1130-1137
Fecha de publicación: 2012
Resumen:
Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ¿ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
DOI: https://doi.org/10.1093/annonc/mdr432
Impacto:
60 citas en
Google Scholar